MP

Manjula Pathak

Active Director Director DIN 10245173
DIN 10245173 First appointment Jul 2023 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Jul 2023
Shareholding value •••• Premium profile

About Manjula Pathak

Data last updated:

Manjula Pathak is a Director at Medifern India Lifesciences Private Limited (since 2023). The company operates in Pharma. Medifern India Lifesciences Private Limited reported revenue of ₹46.8 Lakh (FY 2025).

DIN 10245173
Primary Designation Director
Industry Pharma
First Appointment 19 Jul 2023
Oldest Company Age 3 yrs
Largest company Medifern India Lifesciences Private Limited · ₹46.8 Lakh (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director19 Jul 20232023₹46.8 Lakh (FY 2025)Active

Board colleagues of Manjula Pathak

Directorship timeline

Open interactive timeline →
Medifern India Lifesciences Private Limited
Premium access

Shareholding and investment profile for Manjula Pathak

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Manjula Pathak

Manjula Pathak currently holds 1 directorship: Medifern India Lifesciences Private Limited (Director, since 19 Jul 2023, revenue ₹46.8 Lakh (FY 2025)).

Manjula Pathak was first appointed on 19 Jul 2023 as Director at Medifern India Lifesciences Private Limited.

The current boards of Manjula Pathak's companies include Krishna Murari Pathak (Medifern India Lifesciences Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available